VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice

被引:93
|
作者
Enterlein, S
Warfield, KL
Swenson, DL
Stein, DA
Smith, JL
Gamble, CS
Kroeker, AD
Iversen, PL
Bavari, S
Mühlberger, E
机构
[1] Univ Marburg, Dept Virol, D-35043 Marburg, Germany
[2] USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA
[3] AVI BioPharma Inc, Corvallis, OR USA
关键词
D O I
10.1128/AAC.50.3.984-993.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.
引用
收藏
页码:984 / 993
页数:10
相关论文
共 50 条
  • [31] Mutual Antagonism between the Ebola Virus VP35 Protein and the RIG-I Activator PACT Determines Infection Outcome
    Luthra, Priya
    Ramanan, Parameshwaran
    Mire, Chad E.
    Weisend, Carla
    Tsuda, Yoshimi
    Yen, Benjamin
    Liu, Gai
    Leung, Daisy W.
    Geisbert, Thomas W.
    Ebihara, Hideki
    Amarasinghe, Gaya K.
    Basler, Christopher F.
    CELL HOST & MICROBE, 2013, 14 (01) : 74 - 84
  • [32] Identification of potential inhibitor against Ebola virus VP35: insight into virtual screening, pharmacoinformatics profiling, and molecular dynamic studies
    Bhowmik, Ratul
    Manaithiya, Ajay
    Vyas, Bharti
    Nath, Ranajit
    Rehman, Sara
    Roy, Shubham
    Roy, Ratna
    STRUCTURAL CHEMISTRY, 2022, 33 (03) : 815 - 831
  • [33] Integrated Computational Approach for Virtual Hit Identification against Ebola Viral Proteins VP35 and VP40
    Mirza, Muhammad Usman
    Ikram, Nazia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (11)
  • [34] Identification of Prospective Ebola Virus VP35 and VP40 Protein Inhibitors from Myxobacterial Natural Products
    Hayat, Muhammad
    Gao, Tian
    Cao, Ying
    Rafiq, Muhammad
    Zhuo, Li
    Li, Yue-Zhong
    BIOMOLECULES, 2024, 14 (06)
  • [35] A single immunization with optimized DNA vaccines protects against lethal Ebola virus challenge in mice
    Patel, Ami
    Scott, Veronica
    Wong, Gary
    Reuschel, Emma
    Villarreal, Daniel
    Muthumani, Karuppiah
    Shedlock, Devon
    Yan, Jian
    Tierney, Kevin
    Sardesai, Niranjan
    Kobinger, Gary
    Weiner, David
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [36] Cynarin blocks Ebola virus replication by counteracting VP35 inhibition of interferon-beta production
    Corona, Angela
    Fanunza, Elisa
    Salata, Cristiano
    Morwitzer, Melody Jane
    Distinto, Simona
    Zinzula, Luca
    Sanna, Cinzia
    Frau, Aldo
    Daino, Gian Luca
    Quartu, Marina
    Taglialatela-Scafati, Orazio
    Rigano, Daniela
    Reid, StPatrick
    Mirazimi, Ali
    Tramontano, Enzo
    ANTIVIRAL RESEARCH, 2022, 198
  • [37] Ebola virus VP35 interacts non-covalently with ubiquitin chains to promote viral replication
    Rodriguez-Salazar, Carlos A.
    van Tol, Sarah
    Mailhot, Olivier
    Gonzalez-Orozco, Maria
    Galdino, Gabriel T.
    Warren, Abbey N.
    Teruel, Natalia
    Behera, Padmanava
    Afreen, Kazi Sabrina
    Zhang, Lihong
    Juelich, Terry L.
    Smith, Jennifer K.
    Zylber, Maria Ines
    Freiberg, Alexander N.
    Najmanovich, Rafael J.
    Giraldo, Maria I.
    Rajsbaum, Ricardo
    PLOS BIOLOGY, 2024, 22 (02)
  • [38] Ebola Virus VP35 Interaction with Dynein LC8 Regulates Viral RNA Synthesis
    Luthra, Priya
    Jordan, David S.
    Leung, Daisy W.
    Amarasinghe, Gaya K.
    Basler, Christopher F.
    JOURNAL OF VIROLOGY, 2015, 89 (09) : 5148 - 5153
  • [39] Characterization of the RNA Silencing Suppression Activity of the Ebola Virus VP35 Protein in Plants and Mammalian Cells
    Zhu, Yali
    Cherukuri, Nil Celebi
    Jackel, Jamie N.
    Wu, Zetang
    Crary, Monica
    Buckley, Kenneth J.
    Bisaro, David M.
    Parris, Deborah S.
    JOURNAL OF VIROLOGY, 2012, 86 (06) : 3038 - 3049
  • [40] Ebola Virus VP35 Protein: Modeling of the Tetrameric Structure and an Analysis of Its Interaction with Human PKR
    Banerjee, Anupam
    Mitra, Pralay
    JOURNAL OF PROTEOME RESEARCH, 2020, 19 (11) : 4533 - 4542